A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

Zijing Jia; Kang Wang; Minxiang Xie; Jiajing Wu; Yaling Hu; Yunjiao Zhou; Ayijiang Yisimayi; Wangjun Fu; Lei Wang; Pan Liu; Kaiyue Fan; Ruihong Chen; Lin Wang; Jing Li; Yao Wang; Xiaoqin Ge; Qianqian Zhang; Jianbo Wu; Nan Wang; Wei Wu; Yidan Gao; Jingyun Miao; Yinan Jiang; Lili Qin; Ling Zhu; Weijin Huang; Yanjun Zhang; Huan Zhang; Baisheng Li; Qiang Gao; Xiaoliang Sunney Xie; Youchun Wang; Yunlong Cao; Qiao Wang; Xiangxi Wang

doi:10.1093/procel/pwae033

PDF(12285 KB)

Protein Cell ›› 2024, Vol. 15 ›› Issue (12) : 930-937. DOI: 10.1093/procel/pwae033

LETTER

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

Zijing Jia¹ ,
Kang Wang¹ ,
Minxiang Xie² ,
Jiajing Wu³ ,
Yaling Hu⁴ ,
Yunjiao Zhou⁵ ,
Ayijiang Yisimayi⁶ ,
Wangjun Fu¹ ,
Lei Wang¹ ,
Pan Liu¹ ,
Kaiyue Fan¹ ,
Ruihong Chen¹^,⁷ ,
Lin Wang⁴ ,
Jing Li⁴ ,
Yao Wang⁶ ,
Xiaoqin Ge⁴ ,
Qianqian Zhang² ,
Jianbo Wu² ,
Nan Wang¹ ,
Wei Wu² ,
Yidan Gao² ,
Jingyun Miao⁸ ,
Yinan Jiang⁸ ,
Lili Qin⁸ ,
Ling Zhu¹ ,
Weijin Huang⁴ ,
Yanjun Zhang⁹ ,
Huan Zhang¹⁰ ,
Baisheng Li¹⁰ ,
Qiang Gao⁴ ,
Xiaoliang Sunney Xie⁶^,¹¹ ,
Youchun Wang³^,¹¹ ,
Yunlong Cao⁶^,¹¹ ,
Qiao Wang² ,
Xiangxi Wang¹^,⁷^,¹¹

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Zijing Jia, Kang Wang, Minxiang Xie, Jiajing Wu, Yaling Hu, Yunjiao Zhou, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu, Kaiyue Fan, Ruihong Chen, Lin Wang, Jing Li, Yao Wang, Xiaoqin Ge, Qianqian Zhang, Jianbo Wu, Nan Wang, Wei Wu, Yidan Gao, Jingyun Miao, Yinan Jiang, Lili Qin, Ling Zhu, Weijin Huang, Yanjun Zhang, Huan Zhang, Baisheng Li, Qiang Gao, Xiaoliang Sunney Xie, Youchun Wang, Yunlong Cao, Qiao Wang, Xiangxi Wang. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. Protein Cell, 2024, 15(12): 930‒937 https://doi.org/10.1093/procel/pwae033

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Barnes CO, Jette CA, Abernathy ME et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020a;588:682–687. CrossRef Google scholar

[2]	Cao Y, Yisimayi A, Jian F et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022b;608:593–602. CrossRef Google scholar

[3]	Chalkias S, Harper C, Vrbicky K et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med 2022;387:1279–1291. CrossRef Google scholar

[4]	Fedry J, Hurdiss DL, Wang CY et al. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Sci Adv 2021;7:eabf5632. CrossRef Google scholar

[5]	Gao Q, Bao L, Mao H et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020;369:77–81. CrossRef Google scholar

[6]	Hacisuleyman E, Hale C, Saito Y et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 2021;384:2212–2218. CrossRef Google scholar

[7]	Lv Z, Deng YQ, Ye Q et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 2020;369:1505–1509. CrossRef Google scholar

[8]	Muecksch F, Wang Z, Cho A et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 2022;607:128–134. CrossRef Google scholar

[9]	Walls AC, Park YJ, Tortorici MA et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281–292.e6 e286. CrossRef Google scholar

[10]	Wang Z, Muecksch F, Schaefer-Babajew D et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021f;595:426–431. CrossRef Google scholar

[11]	Wang Z, Schmidt F, Weisblum Y et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021g;592:616–622.

[12]	Wang Q, Guo Y, Zhang RM et al. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis 2023;23:e397–e398. CrossRef Google scholar

[13]	Widge AT, Rouphael NG, Jackson LA et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 2021;384:80–82. CrossRef Google scholar

[14]	Zhao W, Zhao H, Huang B et al. Unravelling the enhanced vaccine immunity by heterologous KCONVAC/Ad5-nCoV COVID-19 vaccination. Signal Transduct Target Ther 2022;7:210. CrossRef Google scholar

[15]	Zhou Y, Liu Z, Li S et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep 2021;34:108699. CrossRef Google scholar